ストックスクリーナーアプリを入手
1.715
3.65%
-0.065
前日終値:
$1.78
開ける：
$1.8001
24時間の取引高:
34,792
Relative Volume:
1.91
時価総額：
$18.50M
収益：
$1.08M
当期純損益:
$-26.95M
株価収益率:
-0.5973
EPS:
-2.8712
ネットキャッシュフロー:
$-21.69M
1週間 パフォーマンス:
-18.72%
1か月 パフォーマンス:
-24.12%
6か月 パフォーマンス:
-43.77%
1年 パフォーマンス:
-68.30%
1日の値動き範囲:
$1.59
$1.8001
1週間の範囲:
$1.59
$2.3899
52週間の値動き範囲:
$1.59
$5.68
Pluri Inc Stock (PLUR) Company Profile
Compare PLUR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
1.715 | 18.50M | 1.08M | -26.95M | -21.69M | -2.8712 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pluri Inc (PLUR) 最新ニュース
Pluri (PLUR) director Doron Shorrer files Form 3 listing share holdings - Stock Titan
PLURPluri Inc Latest SEC Filings - Finviz
Pluri Inc. Q2 2026 Earnings: Wider-than-Expected Loss Drives Stock DeclineSlow Growth Warning - dars.gov.et
Pluri (NASDAQ: PLUR) director logs RSU grant as 625,000 warrants expire - Stock Titan
[SCHEDULE 13D/A] Pluri Inc. Amended Major Shareholder Report - Stock Titan
Synthetic Stem Cell Market to Witness Massive Growth by 2033 | - openPR.com
Form 13D/A Pluri Inc. For: 1 July By Investing.com - Investing.com UK
Price to sales forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Enterprise value to EBITDA forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Price to earnings forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Price to earnings forward of Pluri Inc. – TASE:PLUR - TradingView
Pluri Inc. Actuals & Estimates (NASDAQ:PLUR) - TradingView
Pluri Inc. Actuals & Estimates (FWB:4DX) - TradingView
Pluri Inc. Actuals & Estimates (TASE:PLUR) - TradingView
Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Brevel and Coffeesai Trial Illuminated Fermentation to Push Cell-Based Coffee Toward Commercial Scale - Cultivated X
Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RGNT PE Ratio & Valuation, Is RGNT Overvalued - Intellectia AI
Pluri Secures Insider Advance Subscription to Boost Liquidity - TipRanks
Pluri (NASDAQ: PLUR) gets $1,250,000 insider advance and appoints new director - Stock Titan
PLUR Q1 2026 Earnings: EPS Miss Drives Double-Digit Stock DeclineManagement Tone Analysis - dars.gov.et
Pluri Inc (PLUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pluri Inc (PLUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pluri Inc (PLUR) Institutional Confidence - TradingKey
Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BSX Q1 2026 Earnings: Slight EPS Beat as Core Segments Show ResilienceEPS Growth Report - newsline.com
Pluri Inc. (PLUR) Edges Higher as Stock Nears Key Resistance LevelMarket Leader Picks - newsline.com
Elon Musk Reaches Trillion-Dollar Milestone as SpaceX Nasdaq Debut Propels Net WorthBook Value Growth - newsline.com
Pluri Inc. Q1 2026 Earnings: EPS Misses as Pre-Revenue Biotech Continues Pipeline DevelopmentReturn On Assets - newsline.com
SBSI Q1 2026 Earnings: EPS Surpasses Estimates, No Revenue Data ProvidedAnnual Earnings Summary - newsline.com
PLUR Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentHealthcare Earnings Report - newsline.com
UnitedHealth Raises Dividend 5% Amid Rising Healthcare CostsEarnings Decline Risk - newsline.com
Made Scientific, Pluristyx launch development and manufacturing partnership - ROI-NJ
Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies - The Malaysian Reserve
Pluri subsidiary completes U.S. cosmetic listing for two products By Investing.com - Investing.com Nigeria
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - The Manila Times
Pluri subsidiary completes U.S. cosmetic listing for two products - Investing.com
Two new skin treatments target $90B U.S. aesthetics market - Stock Titan
Pluri's Leap from Lab to Luxury: A High-Stakes Bet on Regenerative Beauty - BriefGlance
Pluri in Good-Faith Talks on EIB Loan Resolution - TipRanks
Pluri Inc. and European Investment Bank continue loan discussions, no enforcement action expected before July - Investing.com
Pluri Biotech Ltd., Pluristem Gmbh, and Pluri Inc. Remain in Constructive Discussions with European Investment Bank Regarding EUR 20 Million Loan - marketscreener.com
Pluri (NASDAQ: PLUR) negotiates with European Investment Bank over €20M loan due 2026 - Stock Titan
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In - Insider Monkey
Steakholder Foods Ltd. (STKH): One of the Best Lab-Grown Meat Stocks to Invest In - Yahoo Finance
7 Best Lab-Grown Meat Stocks to Invest In - Insider Monkey
Pluri Inc. (PLUR) Gains 4.6%, Approaches Resistance at $2.52Breadth Thrust - The Legal Advocate
Plurilock Security Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Plurilock Security Inc.: Plurilock Security Inc. Reports First Quarter 2026 Financial Results - FinanzNachrichten.de
Pluri Inc (PLUR) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):